文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

阿帕贝隆联合标准治疗对近期急性冠脉综合征合并2型糖尿病患者主要不良心血管事件的影响:一项随机临床试验

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01

该随机双盲安慰剂对照试验在13国190个中心纳入2425例近期急性冠脉综合征合并2型糖尿病及低高密度脂蛋白胆固醇患者,比较阿帕贝隆100mg每日两次与安慰剂加标准治疗。

要点

  • 阿帕贝隆未显著降低近期ACS合并2型糖尿病患者的主要不良心血管事件风险。
  • 阿帕贝隆组因不良事件停药比例高于安慰剂组,包括肝酶升高。
  • 该研究为阴性结果,不支持在标准治疗基础上加用阿帕贝隆用于此类人群。

核心结论

  • 在近期急性冠脉综合征、2型糖尿病及低高密度脂蛋白胆固醇患者中,阿帕贝隆加标准治疗未显著降低主要不良心血管事件风险。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在13个国家190个中心开展。
  • 纳入近期7至90天内发生急性冠脉综合征、合并2型糖尿病及低高密度脂蛋白胆固醇的患者。
  • 共随机2425例,阿帕贝隆100mg口服每日两次组1215例,安慰剂组1210例,均加标准治疗。

主要发现

  • 中位随访26.5个月,主要复合终点(心血管死亡、非致死性心肌梗死或卒中)共发生274例。
  • 阿帕贝隆组主要终点发生125例(10.3%),安慰剂组149例(12.4%)。
  • 阿帕贝隆组停药114例(9.4%),安慰剂组69例(5.7%);因肝酶升高停药分别为35例(2.9%)和11例(0.9%)。

临床怎么用

  • 对于近期急性冠脉综合征合并2型糖尿病及低高密度脂蛋白胆固醇患者,不支持在标准治疗基础上加用阿帕贝隆以降低主要不良心血管事件风险。
  • 使用阿帕贝隆时需关注肝酶升高及停药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest favorable effects on clinical outcomes. OBJECTIVE: To test whether apabetalone significantly reduces major adverse cardiovascular events. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019. INTERVENTIONS: Patients were randomized (1:1) to receive apabetalone, 100 mg orally twice daily (n = 1215), or matching placebo (n = 1210) in addition to standard care. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of time to the first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. RESULTS: Among 2425 patients who were randomized (mean age, 62 years; 618 women [25.6%]), 2320 (95.7%) had full ascertainment of the primary outcome. During a median follow-up of 26.5 months, 274 primary end points occurred: 125 (10.3%) in apabetalone-treated patients and 149 (12.4%) in placebo-treated patients (hazard ratio, 0.82 [95% CI, 0.65-1.04]; P = .11). More patients allocated to apabetalone than placebo discontinued study drug (114 [9.4%] vs 69 [5.7%]) for reasons including elevations of liver enzyme levels (35 [2.9%] vs 11 [0.9%]). CONCLUSIONS AND RELEVANCE: Among patients with recent acute coronary syndrome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selective bromodomain and extraterminal protein inhibitor apabetalone added to standard therapy did not significantly reduce the risk of major adverse cardiovascular events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02586155.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ray KK, Nicholls SJ, Buhr KA, et al. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2020. PMID: 32219359. doi:10.1001/jama.2020.3308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。